Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease
Links shared publicly online about this topic.
- 917total visits
Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease
View full resource at medicalnewstoday.com
Tags: Parkinson's Disease, Disease and Condition, Pharma
Most Recently Shared on August 27, 2010 at 1:00 pm By:
Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease http://mnt.to/3HVQ #parkinsons
Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson's disease
news-medical.net — “Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advanced Parkinson's disease (PD) patients with motor fluctuations. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and sustain effective blood concentrations of levodopa, potentially improving PD clinical sympt” View full resource at news-medical.net
Most Recently Shared on August 26, 2010 at 6:42 am By:
Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease: Impax Pharmaceutical... http://bit.ly/9zTMIF
Impax Pharmaceuticals Completes Enrollment In APEX-PD Phase III Trial Of IPX066 In Parkinson's Disease
medicalnewstoday.com — “Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Pha” View full resource at medicalnewstoday.com
Most Recently Shared on April 18, 2010 at 12:05 pm By:
MNT Parkinson's News Health News
Impax Pharmaceuticals Completes Enrollment In APEX-PD Phase III Trial Of IPX066 In Parkinson's Disease http://mnt.to/3Bnv #parkinsons
Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066
news-medical.net — “Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.” View full resource at news-medical.net
Most Recently Shared on April 16, 2010 at 5:40 am By:
Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066: Impax Pharmaceuticals, the brand products ... http://bit.ly/c3e8Vn
Advertisement
